The Importance of Readability: A Guide to Understanding Alopecia Areata through Multilingual Online Resources
DOI:
https://doi.org/10.2340/actadv.v104.41046Keywords:
readability, alopecia areata, JAK-inhibitorsAbstract
Online resources play a vital role in patient education, yet the readability of alopecia areata-related materials remained understudied. A thorough analysis of online alopecia areata-related materials across 5 languages was conducted using Google search. Search terms “alopecia areata” and “alopecia areata treatment” were translated and queried, generating search result lists. The first 50 articles from each list were evaluated for suitability. The materials were categorized into 2 main groups: those focusing on alopecia areata itself and those addressing its treatment. Treatment materials were further divided into subgroups, including Janus kinase inhibitors and other treatment options. Readability was evaluated using the Lix score. The analysis included 251 articles in English, German, French, Italian, and Spanish. The overall mean Lix score was 52 ± 8, which classified them as very hard to comprehend. Articles on alopecia areata treatment had a mean Lix score of 55 ± 8, which was significantly higher (p < 0.001) than those on alopecia areata itself, 50 ± 8. alopecia areata-treatment articles dedicated to JAK inhibitors had an average Lix score of 57 ± 10 and it was significantly higher (p = 0.043) than those on other treatment, 53 ± 6. Online resources on alopecia areata and its treatments remained challenging to comprehend, particularly regarding JAK inhibitors. Improving clarity in patient education materials is crucial for informed decision-making and therapeutic relationships.
Downloads
References
Ho CY, Wu CY, Chen JYF, Wu CY. Clinical and genetic aspects of alopecia areata: a cutting edge review. Genes (Basel) 2023; 14: 1362.
https://doi.org/10.3390/genes14071362 DOI: https://doi.org/10.3390/genes14071362
Husein- ElAhmed H, Husein- ElAhmed S. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: a systematic review and Bayesian network meta- analysis. J Eur Acad Dermatol Venereol 2024; 38: 835-843.
https://doi.org/10.1111/jdv.19797 DOI: https://doi.org/10.1111/jdv.19797
Strazzulla LC, Wang EHC, Avila L, Sicco K Lo, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1-12.
https://doi.org/10.1016/j.jaad.2017.04.1141 DOI: https://doi.org/10.1016/j.jaad.2017.04.1141
Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol 2015; 8: 397-403.
https://doi.org/10.2147/CCID.S53985 DOI: https://doi.org/10.2147/CCID.S53985
Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol 2023; 159: 411-418.
https://doi.org/10.1001/jamadermatol.2023.0002 DOI: https://doi.org/10.1001/jamadermatol.2023.0002
Egeberg A, Linsell L, Johansson E, Durand F, Yu G, Vañó-Galván S. Treatments for moderate-to-severe alopecia areata: a systematic narrative review. Dermatol Ther (Heidelb) 2023; 13: 2951-2991.
https://doi.org/10.1007/s13555-023-01044-5 DOI: https://doi.org/10.1007/s13555-023-01044-5
Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev 2008: CD004413.
https://doi.org/10.1002/14651858.CD004413.pub2 DOI: https://doi.org/10.1002/14651858.CD004413.pub2
Fukuyama M, Ito T, Ohyama M. Alopecia areata: current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol 2022; 49: 19-36.
https://doi.org/10.1111/1346-8138.16207 DOI: https://doi.org/10.1111/1346-8138.16207
Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol 2020; 83: 123-130.
https://doi.org/10.1016/j.jaad.2020.03.004
European Medicines Agency. Olumiant [cited 2024 Mar 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant.
Pfizer. European Commission approves Pfizer's LITFULOTM for adolescents and adults with severe alopecia areata. 2023 [cited 2024 Mar 12]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-litfulotm-adolescents.
Pfizer. FDA approves Pfizer's LITFULOTM (ritlecitinib) for adults and adolescents with severe alopecia areata. 2023 [cited 2024 Mar 12]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and.
Lilly. FDA approves Lilly and Incyte's OLUMIANT® (baricitinib) as first and only systemic medicine for adults with severe alopecia areata. 2022 [cited 2024 Mar 12]. Available from: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lilly-and-incytes-olumiantr-baricitinib-first-and.
Numata T, Irisawa R, Mori M, Uchiyama M, Harada K. Baricitinib therapy for moderate to severe alopecia areata: a retrospective review of 95 Japanese patients. Acta Derm Venereol 2024; 104: adv18348.
https://doi.org/10.2340/actadv.v104.18348 DOI: https://doi.org/10.2340/actadv.v104.18348
Moreno-Vílchez C, Bonfill-Ortí M, Bauer-Alonso A, Notario J, Figueras-Nart I. Baricitinib for the treatment of alopecia areata in adults: real-world analysis of 36 patients. J Am Acad Dermatol 2024; 90: 1059-1061.
https://doi.org/10.1016/j.jaad.2023.09.089 DOI: https://doi.org/10.1016/j.jaad.2023.09.089
De Greef A, Thirion R, Ghislain PD, Baeck M. Real-life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1-year follow-up data. Dermatol Ther (Heidelb) 2023; 13: 2869-2877.
https://doi.org/10.1007/s13555-023-01030-x DOI: https://doi.org/10.1007/s13555-023-01030-x
Borgmann H, Mager R, Salem J, Bruendl J, Kunath F, Thomas C, et al. Robotic prostatectomy on the web: a cross-sectional qualitative assessment. Clin Genitourin Cancer 2016; 14: e355-e362.
https://doi.org/10.1016/j.clgc.2015.12.020 DOI: https://doi.org/10.1016/j.clgc.2015.12.020
Borgmann H, Wölm JH, Vallo S, Mager R, Huber J, Breyer J, et al. Prostate cancer on the web: expedient tool for patients' decision-making? J Cancer Educ 2017; 32: 135-140.
https://doi.org/10.1007/s13187-015-0891-3 DOI: https://doi.org/10.1007/s13187-015-0891-3
Prestin A, Vieux SN, Chou W ying S. Is online health activity alive and well or flatlining? Findings from 10 years of the Health Information National Trends Survey. J Health Commun 2015; 20: 790-798.
https://doi.org/10.1080/10810730.2015.1018590 DOI: https://doi.org/10.1080/10810730.2015.1018590
statistica.com. Market share of leading search engines worldwide from January 2015 to January 2024 [Internet]. 2024 [cited 2024 Mar 6]. Available from: https://www.statista.com/statistics/1381664/worldwide-all-devices-market-share-of-search-engines/
Google Inc. How Google determines the language of search results [Internet] [cited 2024 Mar 6]. Available from: https://support.google.com/websearch/answer/13511324?hl=en-PL&visit_id=638453336335039611-245544975&p=language_search_results&rd=1#zippy=%2Cdisplay-language-setting
Cuan-Baltazar JY, Muñoz-Perez MJ, Robledo-Vega C, Pérez-Zepeda MF, Soto-Vega E. Misinformation of COVID-19 on the Internet: Infodemiology Study. JMIR Public Health Surveill 2020; 6: e18444.
https://doi.org/10.2196/18444 DOI: https://doi.org/10.2196/18444
Beauharnais CC, Aulet T, Rodriguez-Silva J, Konen J, Sturrock PR, Alavi K, et al. Assessing the quality of online health information and trend data for colorectal malignancies. J Surg Res 2023; 283: 923-928.
https://doi.org/10.1016/j.jss.2022.10.055 DOI: https://doi.org/10.1016/j.jss.2022.10.055
Keating D. Despite Brexit, English remains the EU's most spoken language by far. Forbes Retrieved 2020; 7.
Calafato R, Gudim F. Literature in contemporary foreign language school textbooks in Russia: content, approaches, and readability. Language Teach Res 2022; 26: 826-846.
https://doi.org/10.1177/1362168820917909 DOI: https://doi.org/10.1177/1362168820917909
Anderson J. Lix and rix: variations on a little-known readability index. J Reading 1983; 26: 490-496.
Lee H, Huang KP, Mostaghimi A, Choudhry NK. Treatment patterns for alopecia areata in the US. JAMA Dermatol 2023; 159: 1253-1257.
https://doi.org/10.1001/jamadermatol.2023.3109 DOI: https://doi.org/10.1001/jamadermatol.2023.3109
Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol 2020; 83: 123-130.
https://doi.org/10.1016/j.jaad.2020.03.004 DOI: https://doi.org/10.1016/j.jaad.2020.03.004
Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol 2024; 38: 687-694.
https://doi.org/10.1111/jdv.19768 DOI: https://doi.org/10.1111/jdv.19768
Dainichi T, Iwata M, Kaku Y. Alopecia areata: what's new in the diagnosis and treatment with JAK inhibitors? J Dermatol 2024; 51: 196-209.
https://doi.org/10.1111/1346-8138.17064 DOI: https://doi.org/10.1111/1346-8138.17064
Tan SSL, Goonawardene N. Internet health information seeking and the patient-physician relationship: a systematic review. J Med Internet Res 2017; 19: e9.
https://doi.org/10.2196/jmir.5729 DOI: https://doi.org/10.2196/jmir.5729
readable.com [cited 2023 Mar 19]. Available from: https://readable.com/blog/the-lix-and-rix-readability-formulas/
eurostat. Educational attainment statistics [cited 2023 Mar 19]. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Educational_attainment_statistics#Educational_attainment_levels_vary_between_age_groups.
Björnsson CH. Readability of newspapers in 11 languages. Read Res Q 1983; 480-497.
https://doi.org/10.2307/747382 DOI: https://doi.org/10.2307/747382
Published
How to Cite
License
Copyright (c) 2024 Tomasz Skrzypczak, Anna Skrzypczak, Jacek C. Szepietowski
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
